Our best chance to end cancer
The FDA’s first ever approval of Kymriah, a CAR-T drug for acute childhood leukaemia, was a milestone for immuno-oncology and has justifiably hit the headlines. But it is far from the end of the story, as a long study from Dr John Savin and Dr Daniel Wilkinson of Edison Research makes clear.
CRISPR ‘it has incredible potential to improve our world
Today we are able to use CRISPR to disable target genes and to add new stretches of DNA. One of the impressive aspects of Doudna’s book is her confidence in these techniques.